Cargando…

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

BACKGROUND: Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tischkowitz, Marc, Brunet, Jean-Sébastien, Bégin, Louis R, Huntsman, David G, Cheang, Maggie CU, Akslen, Lars A, Nielsen, Torsten O, Foulkes, William D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948892/ https://www.ncbi.nlm.nih.gov/pubmed/17650314 http://dx.doi.org/10.1186/1471-2407-7-134

Ejemplares similares

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
por: Rajput, Ashish B., et al.
Publicado: (2007)

Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification
por: Tovey, Holly, et al.
Publicado: (2019)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2020)

Clinicopathlogic and Immunohistochemical Characteristics of Triple Negative Invasive Lobular Carcinoma
por: Koo, Ja Seung, et al.
Publicado: (2011)

Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer
por: Goffin, J R, et al.
Publicado: (2003)

Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer
por: Sjekloča, Nikoleta, et al.
Publicado: (2020)

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer
por: Cubukcu, Erdem, et al.
Publicado: (2014)

A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression
por: Kalyanasundaram, Swaminathan, et al.
Publicado: (2022)

Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers
por: Korlimarla, Aruna, et al.
Publicado: (2022)

Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers
por: Liu, Yan-Xi, et al.
Publicado: (2016)

Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
por: Sun, Woo Young, et al.
Publicado: (2016)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

Update on triple-negative breast cancer: prognosis and management strategies
por: Brouckaert, Olivier, et al.
Publicado: (2012)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
por: Cserni, Gábor, et al.
Publicado: (2021)

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer
por: Ouyang, Mao, et al.
Publicado: (2015)

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer
por: Ma, Fei, et al.
Publicado: (2014)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2018)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abuderman, Abdulwahab A., et al.
Publicado: (2020)

Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target
por: Salama, Maha E, et al.
Publicado: (2021)

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
por: Schmidt, Gilda, et al.
Publicado: (2022)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Bastiaansen, Anna E. M., et al.
Publicado: (2020)

Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers
por: Yue, Yong, et al.
Publicado: (2016)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study
por: Wu, Wenyu, et al.
Publicado: (2019)

Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
por: Li, Yuan, et al.
Publicado: (2022)

The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer
por: Wu, Sijia, et al.
Publicado: (2021)

Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
por: Pu, Shengyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5laju8aok394k3jlgac1a2559n